Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

[Vitamin D for prevention of diseases?].
Improved self-efficacy in persons with relapsing remitting multiple sclerosis after an intensive social cognitive wellness program with participation of support partners: a 6-months observational study.
1,25-Dihydroxyvitamin D3 acts directly on the T lymphocyte vitamin D receptor to inhibit experimental autoimmune encephalomyelitis.
Early pathological alterations of lower lumbar cords detected by ultrahigh-field MRI in a mouse multiple sclerosis model.
Corticosteroids for treating optic neuritis.
The Submaximal Clinical Exercise Tolerance Test (SXTT) to Establish Safe Exercise Prescription Parameters for Patients with Chronic Disease and Disability.
Endogenous opioids regulate the expression of inducible nitric oxide synthase by splenocytes.
Diagnosis of exclusion: a case report of probable glatiramer acetate-induced eosinophilic myocarditis.
Vorinostat, a histone deacetylase inhibitor, suppresses dendritic cell function and ameliorates experimental autoimmune encephalomyelitis.
[Controlled research on multiple sclerosis treated with electroacupuncture and acupoint injection].
Cigarette Smoking and Activities of Daily Living in Ocular Myasthenia Gravis.
Novartis receives European Commission approval for Gilenya®, the first oral multiple sclerosis treatment for use in the EU
Olive oil phenols and neuroprotection.
BG-12 (dimethyl fumarate): a review of mechanism of action, efficacy, and safety.
Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
No impact of current therapeutic strategies on disease reactivation after natalizumab discontinuation: a comparative analysis of different approaches during the first year of natalizumab discontinuation.
In vitro Biological Characterization of IFN-β-1a major Glycoforms.
Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis.
In vivo evidence of glutamate toxicity in multiple sclerosis.
Prolonged-release fampridine and walking and balance in MS: randomised controlled MOBILE trial.
Natalizumab affects the T-cell receptor repertoire in patients with multiple sclerosis.
Modulation of Sox10, HIF-1α, Survivin, and YAP by Minocycline in the Treatment of Neurodevelopmental Handicaps following Hypoxic Insult.
A Study to Evaluate the Effectiveness, Tolerability and Safety of Laquinimod
Cerebrospinal fluid detection of interleukin-1beta in phase of remission predicts disease progression in multiple sclerosis.
Evaluation of Dalfampridine Extended Release 5 and 10 mg in Multiple Sclerosis: A Randomized Controlled Trial.

Pages